Inactive Instrument

ANTA PHAR Stock Nasdaq

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

18-07-02	Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index	CI
18-06-27	Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index	CI

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Google lets you customize your preferred sources.

Choose MarketScreener

Market Cap	681K 595K 549K 506K 954K 65.55M 975K 6.56M 2.58M 32.1M 2.56M 2.5M 111M	P/E 2016	-0.4x	P/E 2017	-0.58x
Enterprise Value	-1.52M -1.32M -1.22M -1.13M -2.12M -146M -2.17M -14.61M -5.74M -71.47M -5.69M -5.57M -246M	EV / Sales 2016	44,069,434x	EV / Sales 2017	-
Free-Float	100%	Yield 2016 *	-	Yield 2017	-

18-07-02	Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index	CI
18-06-27	Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index	CI
18-03-12	Anthera Pharmaceuticals, Inc. Reports Top Line Data from the Result Phase 3 Clinical Study of Sollpura	CI
18-03-12	Anthera Pharmaceuticals, Inc. - Special Call
18-03-06	Anthera Mulls Acquisitions	CI
18-03-05	Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	CI
18-02-05	Anthera Pharmaceuticals, Inc. Concludes Last Patient Visit in the Phase 3 Result Clinical Study of Sollpura	CI
18-01-08	Anthera Pharmaceuticals, Inc. announced that it has received $15 million in funding from a group of investors	CI
18-01-03	Anthera Pharmaceuticals, Inc. Appoints Patrick Murphy as Senior Vice President, Manufacturing	CI
17-12-11	Anthera Pharmaceuticals, Inc. Announces Positive Outcome of Interim Futility Analysis in the Phase 3 Result Clinical Study of Sollpura	CI
17-11-09	Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura	CI
17-11-06	Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	CI
17-10-22	Anthera Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from a group of investors	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-7.17%	-4.39%	+42.72%	+73.32%	52.1B
ARGENX SE	+0.24%	-1.54%	+52.85%	+71.85%	53.83B
INSMED INCORPORATED	+0.80%	-6.31%	+5.62%	+417.78%	23.48B
BIONTECH SE	-0.09%	-0.01%	-16.85%	-15.41%	23.13B
WUXI BIOLOGICS (CAYMAN) INC.	-5.95%	-2.58%	+29.53%	-9.47%	19.36B
GENMAB A/S	-1.14%	+0.03%	+31.67%	-30.65%	17.56B
PHARMAESSENTIA CORPORATION	-5.16%	-7.00%	+168.44%	+314.96%	15.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.91%	-5.83%	+25.17%	+644.30%	14.83B
EXELIXIS, INC.	+0.43%	-1.03%	+25.75%	+189.74%	14.06B
Average	-2.77%	-2.62%	+40.54%	+184.05%	25.95B
Weighted average by Cap.	-2.80%	-2.36%	+39.55%	+143.13%

	2016	2017
Net sales	0.14 0.13 0.12 0.11 0.2 13.96 0.21 1.4 0.55 6.84 0.54 0.53 23.54	-
Net income	-55.52M -48.52M -44.77M -41.27M -77.79M -5.35B -79.51M -535M -210M -2.62B -209M -204M -9.01B	-26.87M -23.49M -21.67M -19.98M -37.65M -2.59B -38.49M -259M -102M -1.27B -101M -98.71M -4.36B
Net Debt	-20.84M -18.21M -16.81M -15.49M -29.2M -2.01B -29.85M -201M -79.02M -983M -78.28M -76.56M -3.38B	-2.2M -1.92M -1.77M -1.63M -3.08M -211M -3.14M -21.17M -8.33M -104M -8.25M -8.07M -357M

ANTA PHAR Stock Nasdaq

Stocks

Biotechnology & Medical Research

Valuation: ANTA PHAR

Latest news : ANTA PHAR

Bio Therapeutic Drugs

Financials

Company Profile